GKIM
BCRX icon

GW&K Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

GW&K Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7M Sell
3,171,113
-69,349
-2% -$627K 0.25% 152
2026
Q1 		$30.9M Buy
3,240,462
+79,538
+3% +$618K 0.27% 137
2025
Q4 		$24.7M Buy
3,160,924
+963,159
+44% +$6.96M 0.21% 179
2025
Q3 		$16.7M Sell
2,197,765
-425,772
-16% -$3.55M 0.15% 223
2025
Q2 		$23.5M Sell
2,623,537
-261,143
-9% -$2.43M 0.21% 180
2025
Q1 		$21.6M Sell
2,884,680
-56,716
-2% -$457K 0.2% 190
2024
Q4 		$22.1M Sell
2,941,396
-336,204
-10% -$2.55M 0.19% 194
2024
Q3 		$24.9M Sell
3,277,600
-127,100
-4% -$966K 0.21% 186
2024
Q2 		$21M Sell
3,404,700
-49,208
-1% -$272K 0.19% 190
2024
Q1 		$17.5M Buy
3,453,908
+1,116,225
+48% +$6.28M 0.15% 205
2023
Q4 		$14M Sell
2,337,683
-233,180
-9% -$1.35M 0.13% 214
2023
Q3 		$18.2M Sell
2,570,863
-27,379
-1% -$197K 0.18% 188
2023
Q2 		$18.3M Sell
2,598,242
-5,689
-0.2% -$45.7K 0.17% 191
2023
Q1 		$21.7M Buy
2,603,931
+876,844
+51% +$8.44M 0.21% 169
2022
Q4 		$19.8M Buy
1,727,087
+309,947
+22% +$3.87M 0.2% 178
2022
Q3 		$17.9M Buy
+1,417,140
New +$18.2M 0.2% 177

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

GW&K Investment Management's BCRX Position: Q2 2026 in Review

GW&K Investment Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 2.1% in Q2 2026, selling an estimated $627K and leaving 3,171,113 shares worth $31.7M. The position accounts for 0.25% of the portfolio, ranked #152.

GW&K Investment Management first reported a position in BCRX in Q3 2022 and has held it in 16 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • GW&K Investment Management held 3,171,113 shares of BioCryst Pharmaceuticals worth $31.7M as of Q2 2026.
  • GW&K Investment Management sold 69,349 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $627K.
  • BioCryst Pharmaceuticals made up 0.25% of GW&K Investment Management's portfolio in Q2 2026, its #152 holding.
  • GW&K Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.